We are live on ! Find out more

219 hedge funds and large institutions have $1.28B invested in Genmab in 2025 Q1 according to their latest regulatory filings, with 37 funds opening new positions, 92 increasing their positions, 66 reducing their positions, and 41 closing their positions.

New
Increased
Maintained
Reduced
Closed

63% more call options, than puts

Call options by funds: $15.4M | Put options by funds: $9.44M

39% more repeat investments, than reductions

Existing positions increased: 92 | Existing positions reduced: 66

6.18% more ownership

Funds ownership: 91.86%98.04% (+6.2%)

1% more capital invested

Capital invested by funds: $1.27B → $1.28B (+$10.3M)

10% less first-time investments, than exits

New positions opened: 37 | Existing positions closed: 41

4% less funds holding

Funds holding: 228219 (-9)

Holders
219
Holders Change
-9
Holders Change %
-3.95%
% of All Funds
2.94%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.01%
New
37
Increased
92
Reduced
66
Closed
41
Calls
$15.4M
Puts
$9.44M
Net Calls
+$5.98M
Net Calls Change
+$3.42M

GMAB Hedge Fund Activity: Q1 2025 in Review

219 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in Genmab (GMAB) for Q1 2025, worth a combined $1.28B — up 0.81% from $1.27B a quarter earlier.

Sellers outnumbered buyers: 41 funds closed out of GMAB and 37 opened new positions — a net loss of 4 holders — while 66 trimmed existing stakes and 92 added.

The largest buyer was Orbis Allan Gray, adding an estimated $60.7M. The largest seller was Capital International Investors, exiting entirely with an estimated $53.4M sold.

  • 219 institutional investors held Genmab (GMAB) as of Q1 2025, down from 228 in Q4 2024.
  • Funds reported $1.28B of Genmab stock for Q1 2025, up 0.81% quarter-over-quarter.
  • 37 funds opened new Genmab positions in Q1 2025 and 41 closed out, a net change of -4 holders.
  • The largest Genmab buyer in Q1 2025 was Orbis Allan Gray, an estimated $60.7M added.
  • The largest Genmab seller in Q1 2025 was Capital International Investors, an estimated $53.4M sold.

Based on aggregated 13F filings for Q1 2025.